Corbus Pharmaceuticals Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Corbus Pharmaceuticals Holdings şirketinin kazançlarının yıllık 26% oranında düşmesi, yıllık gelirinin ise yıllık 74.1% oranında artması bekleniyor. EPS'nin yıllık 9.3% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-26.0%

Kazanç büyüme oranı

-9.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	26.7%
Gelir büyüme oranı	74.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	02 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Dec 06

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Jun 12

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

May 14

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Mar 11

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04

Corbus Pharmaceuticals: Down But Not Out

Jan 29

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Jan 09

Corbus's lenabasum shows benefit in autoimmune disorder

Nov 09

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CRBP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	4	-143	-115	-171	8
12/31/2026	5	-89	-70	-70	8
12/31/2025	1	-67	-51	-48	8
12/31/2024	N/A	-46	-51	-36	8
9/30/2024	N/A	-39	-37	-37	N/A
6/30/2024	N/A	-35	-30	-30	N/A
3/31/2024	N/A	-34	-29	-29	N/A
12/31/2023	N/A	-45	-36	-36	N/A
9/30/2023	N/A	-47	-38	-38	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-51	-42	-42	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-42	-40	-40	N/A
6/30/2022	0	-35	-32	-32	N/A
3/31/2022	0	-39	-37	-37	N/A
12/31/2021	1	-46	-48	-48	N/A
9/30/2021	2	-44	-57	-57	N/A
6/30/2021	3	-77	-85	-85	N/A
3/31/2021	3	-98	-94	-94	N/A
12/31/2020	4	-111	-100	-100	N/A
9/30/2020	6	-129	-106	-104	N/A
6/30/2020	7	-115	-97	-94	N/A
3/31/2020	36	-75	-87	-84	N/A
12/31/2019	36	-71	-48	-46	N/A
9/30/2019	35	-62	-39	-37	N/A
6/30/2019	34	-56	-30	-29	N/A
3/31/2019	6	-70	-19	-18	N/A
12/31/2018	5	-56	-32	-30	N/A
9/30/2018	3	-49	-28	-25	N/A
6/30/2018	3	-41	N/A	-23	N/A
3/31/2018	2	-37	N/A	-23	N/A
12/31/2017	2	-32	N/A	-28	N/A
9/30/2017	3	-29	N/A	-24	N/A
6/30/2017	3	-28	N/A	-21	N/A
3/31/2017	3	-25	N/A	-18	N/A
12/31/2016	2	-20	N/A	-14	N/A
9/30/2016	2	-15	N/A	-9	N/A
6/30/2016	1	-12	N/A	-8	N/A
3/31/2016	1	-10	N/A	-6	N/A
12/31/2015	1	-9	N/A	-5	N/A
9/30/2015	0	-8	N/A	-5	N/A
6/30/2015	0	-6	N/A	-3	N/A
3/31/2015	N/A	-4	N/A	-4	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CRBP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CRBP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CRBP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CRBP şirketinin gelirinin (yıllık 74.1% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CRBP şirketinin gelirinin (yıllık 74.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CRBP 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/10 05:50
Gün Sonu Hisse Fiyatı	2025/01/08 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Corbus Pharmaceuticals Holdings, Inc. 20 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kalpit Patel	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Corbus Pharmaceuticals Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 9.9% to US$56.78

Price target decreased by 13% to US$71.00

Price target increased to US$2.20

Price target increased to US$2.20

Consensus forecasts updated

Price target decreased to US$1.65

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Price target decreased by 9.9% to US$56.78

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

New minor risk - Shareholder dilution

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.65

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Consensus revenue estimates fall to US$2.32m

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Consensus revenue estimates increase to US$3.68m

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

Consensus forecasts updated

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

New 90-day high: US$2.58

Corbus Pharmaceuticals: Down But Not Out

New 90-day high: US$1.61

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Price target lowered to US$1.88